Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Cash from Investing Activities (2020 - 2025)

Historic Cash from Investing Activities for Tango Therapeutics (TNGX) over the last 6 years, with Q3 2025 value amounting to $47.5 million.

  • Tango Therapeutics' Cash from Investing Activities rose 4576.91% to $47.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $146.9 million, marking a year-over-year increase of 11630.79%. This contributed to the annual value of $86.1 million for FY2024, which is 10790.32% up from last year.
  • As of Q3 2025, Tango Therapeutics' Cash from Investing Activities stood at $47.5 million, which was up 4576.91% from $16.8 million recorded in Q2 2025.
  • Over the past 5 years, Tango Therapeutics' Cash from Investing Activities peaked at $52.1 million during Q4 2024, and registered a low of -$152.2 million during Q3 2021.
  • Its 5-year average for Cash from Investing Activities is $3.4 million, with a median of $16.8 million in 2025.
  • Per our database at Business Quant, Tango Therapeutics' Cash from Investing Activities surged by 63574.34% in 2022 and then crashed by 47210.4% in 2023.
  • Quarter analysis of 5 years shows Tango Therapeutics' Cash from Investing Activities stood at -$45.2 million in 2021, then skyrocketed by 72.12% to -$12.6 million in 2022, then surged by 368.56% to $33.9 million in 2023, then soared by 53.79% to $52.1 million in 2024, then dropped by 8.8% to $47.5 million in 2025.
  • Its last three reported values are $47.5 million in Q3 2025, $16.8 million for Q2 2025, and $30.6 million during Q1 2025.